Trials / Completed
CompletedNCT02615496
Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept
Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: An Observational Postauthorisation Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 716 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will be an observational, cross-sectional study of knowledge, understanding, and self-reported behavior among a sample of physicians and patients with recent aflibercept experience in a total of up to five European countries.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video. |
| BEHAVIORAL | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet "Your guide to EYLEA," patient information leaflet, and audio CD. |
Timeline
- Start date
- 2015-12-07
- Primary completion
- 2016-09-30
- Completion
- 2017-01-31
- First posted
- 2015-11-26
- Last updated
- 2017-09-15
Locations
5 sites across 5 countries: France, Germany, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02615496. Inclusion in this directory is not an endorsement.